Interestingly, a clinical trial with systemic sclerosis patients showed that THBS1 expression rapidly declined in patients’ skin after the treatment with Fresolimumab, a high-affinity neutralizing antibody targeting TGFβ158. Here, THBS1 is linked to systemic sclerosis.